1. Home
  2. HGLB vs TNXP Comparison

HGLB vs TNXP Comparison

Compare HGLB & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Highland Global Allocation Fund

HGLB

Highland Global Allocation Fund

HOLD

Current Price

$9.16

Market Cap

207.7M

Sector

Finance

ML Signal

HOLD

Logo Tonix Pharmaceuticals Holding Corp.

TNXP

Tonix Pharmaceuticals Holding Corp.

HOLD

Current Price

$16.26

Market Cap

201.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HGLB
TNXP
Founded
1998
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
207.7M
201.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
HGLB
TNXP
Price
$9.16
$16.26
Analyst Decision
Buy
Analyst Count
0
1
Target Price
N/A
$70.00
AVG Volume (30 Days)
91.8K
509.0K
Earning Date
01-01-0001
11-10-2025
Dividend Yield
13.16%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$10,299,000.00
Revenue This Year
N/A
$2.96
Revenue Next Year
N/A
$750.19
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.42
$6.76
52 Week High
$9.45
$69.97

Technical Indicators

Market Signals
Indicator
HGLB
TNXP
Relative Strength Index (RSI) 39.98 37.99
Support Level $8.96 $17.71
Resistance Level $9.39 $19.35
Average True Range (ATR) 0.24 1.07
MACD -0.01 -0.21
Stochastic Oscillator 24.88 5.40

Price Performance

Historical Comparison
HGLB
TNXP

About HGLB Highland Global Allocation Fund

Highland Global Allocation Fund is a diversified, closed-end management investment company. The investment objective of the Fund is to seek long-term growth of capital and future income. The Fund seeks to achieve its investment objectives by investing in a portfolio of U.S. and foreign equity, debt, and money market securities. It may also invest in senior loans to domestic or foreign corporations, partnerships, and other entities that operate in a variety of industries and geographic regions.

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.

Share on Social Networks: